- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
More ▼
Key statistics
As of last trade Cytodyn Inc (296:STU) traded at 0.135, 3.85% above its 52-week low of 0.13, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.135 |
---|---|
High | 0.135 |
Low | 0.134 |
Bid | 0.135 |
Offer | 0.156 |
Previous close | 0.132 |
Average volume | 22.61k |
---|---|
Shares outstanding | 986.06m |
Free float | 978.09m |
P/E (TTM) | -- |
Market cap | 148.75m USD |
EPS (TTM) | -0.055 USD |
Data delayed at least 15 minutes, as of Apr 18 2024.
More ▼